A patient is described with recurrent pulmonary embolus following combined therapy of placement of a caval umbrella device for caval interruption and anticoagulation. The source of this embolus was felt to be from a thrombus located on the proximal portion of the umbrella. This is the first reported instance of this complication.
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SELECTED REPORTS
Recurrent Pulmonary Embolus after
Insertion of lntracaval Prosthesis* A patient is described with recurrent pulmonary embolus following combined therapy of placement of a caval umbrella device for caval interruption and anticoagulation. The source of this embolus was felt to be from a thrombus located on the proximal portion of the umbrella. This is the first reported instance of this complication.
The vena cava umbrella device for prevention of pulmonary emboli has found wide acceptance since Mobin-Uddin et al' first described it in 1967. Recurrent pulmonary emboli, after placement of the intracaval device, have been infrequent,25 occurring in less than 2 percent of insertions. This report concerns a patient who developed a pulmonary embolus after placement of the caval umbrella. A thrombus located on the proximal surface of the device was felt to be the source of embolization.
CASE REPORT
A 67-year-old white woman was hospitalized in January, 1972 for removal of an impacted gallstone in the remnant of her cystic duct (cholecystectomy had been performed 20 years previously). History revealed chronic intermittent edema of the lower left leg resulting from a previous episode of phlebitis. The postoperative period following the second operation was characterized by congestive heart failure and hronchopneimmiionia. On the day of discharge, the patient developed left upper quadrant abdominal pain of a plemmritic nature. This subsequently cleared only to recur three days later. She was re-hospitalized and fotmndto have normal vital signs except for pulse rate of 120. Auscultation of the lungs revealedl the' presence of bilateral basilar rales. Moderate left upper quadrant abdominal tenderness was noted. Swelling of the left lower extremity was present, but there was no calf tenderness or Homan's sign. Chest x-ray examination and electrocardiogram were unremarkable. The hematocrit was 37 volumes percent, the WBC count 9,800 cells per cubic mm with a normal dlifferential count. Arterial blood gases revealed Po2 58 mm Hg, Pco2 of 37.6 mm Hg, and pH 7.4. The LDH was 400 units and the SCOT, CPK and SGPT were normal. Lung scan revealed multiple bilateral areas of decreased perfusion felt to represent mnmmltiple pulmonary ensboli (Fig 1) . Subcutaneous heparin (75 mg) was given every six hours. The Lee White clotting time was maintained at two to three times the control value of seven minutes. Commmadin was institsmtedsimultaneously in therapeutic closes and the'prothromhin time was prolonged to twice the control valmme of 12 seconds.
Two days after admission, the patient developed right #{176}Fromm the Departments of Medicine and Radiology, Memorial Medical Center, Savannah, Georgia. pleuritic chest pain associated with increasing rates over the right lower lung. It was felt she had sustained another emishohms despite adequate antmcoagulation. A vena cava umbrella was placed! at the level of the fosmrth lumbar vertebrae. The heparin was withdrawn four days later, hut coimmadin was continued.
The patient did well until 14 days later when she developed confusion and dyspnea. Lung scan demonstrated adequate perfusion of the previously underperfumsed areas, hut with a new extensive flow deficit to the entire right upper lobe (Fig 2) . The LDH was 350 units. In an attempt to determine the source of this new embolus, a bilateral femoral iliac venagramluwas performed. This revealed nearly complete occlusion of the left iliac vein with extensive collateral development presumahly secondary to the chronic phlebitis. There was a 2 cmnin diameter thromhms located on the proximal surface of the tmml)rella (Fig 3) . The vena cava was patent above the device and there was flow of contrast material through and arotmndthe device via collaterals. It was felt that this thrombus was the source of embolization. Intravenous heparin therapy (50 mg ('very foumrhoumrs)was instituted. The patient gradually improved and her clinical findings cleared.
Seven days later, repeat venacavagram disclosed persistent patency of the cava with no change in the thrombus. Repeat lung scan showed retumrnof nonnal perfusion to the right upper lobe. She was discharged 14 (lays after the recurrent embolus on 5 mngcommmnadin per day. have been noted after placement. Similar results have been noted in 20 instamices at this hospital with only one recurrence. This patient had a caval umbrella placed after failure of heparin therapy to prevent repeated emboli. Despite insertion of the umbrella and continuation of anticoagulant therapy, the patient had another pulmonary embolus which was confirmed both clinically and radiologically (Fig2).
In the majority of patients, thrombotic occlusion of the inferior vena cava via the umbrella usually occurs within one to two weeks after insertion.6 However, a few patients continue to have free flow of blood through the prosthesis, as in this patient (Fig 3) . A thrombus usually forms on the proximal surface of the umbrella in all patients and such a thrombus was demonstrated in this patient (Fig 3) . These thrombi eventually endothelialize and become fibrotic within six to eight weeks. Such clots do not usually propagate proximally or act as sources of further embolization.
The proximity of the renal vein usually prevents propagation. Since the vena cava remained patent in this case and the thrombus was demonstrated on the proximal surface of the umbrella, it was felt that this was the source of the embolus. Perhaps the low insertion at the level of the L4 vertebral body is responsible for propagation of clot in this instance. The recurrent embolus took place two weeks after placement of the device. This period of time is within the usual six to eight weeks required for endothelializatiorm and fibrosis of the proximal thrombus. Although a medium sized collateral vessel was demonstrated in the region of the umbrella, this was not felt to be the route of the recurrent embolus. We believe that the diameter of this collateral vessel was not sufficient to allow passage of an embolus of this size unless numerous small emboli followed precisely the same pathway to the pulmonary vasculature of the right upper lobe. This seems to be a very remote possibility. An ovarian vein route for this embolus seems doubtful in view of the more obvious source. We believe that this report demonstrates that a thrombus located on the proximal portion of the caval umbrella in association with free flow of blood through the prosthesis may give rise to repeated pulmonary emboli.
Mobin-Uddin et al suggest continuation of heparin therapy for five to seven days after insertion of the prosthesis. This patient was maintained on heparin therapy for four days after placement. Coumadin, which had been instituted at the time of admission in full therapeutic doses, was continued following withdrawal of heparin. Perhaps prolonged administration of heparin would have prevented this complication.
This report clearly demonstrates the need for continued vigilance regarding recurrent pulmonary emboli during the initial several weeks following insertion of the vena cava device. An increased awareness of this possibihty may reveal this sequence of events to be more frequent than formerly presumed. This case also reveals the importance of proper placement of the caval umbrella at the L3 level so that the renal veins will prevent propagation of thrombus from the proximal portion of the umbrella and also the need for continued heparin administration during the critical period following prosthesis insertion. Ski n rash, gastrointestinal irritation, hirsutism, gynecomastia, and muscular weakness are adverse reactions related to the use of the potassium-sparing diuretic, spironolactone. ' The side effects are usually infrequent and mild. The most serious complication is related to its potassium-sparing effect which may induce dangerous and even fatal hyperkalemia. The following case report presents an occurrence of severe hvperkalemia after the excessive use of spironolactone, resulting in ventricular standstill, and survival after treatment with sodium bicarbonate.
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CASE REPORT
A 69-year-old man was l)rotmght to the emnergency room of There was no atrial activity noted (Fig 1B) . The effect of hyperkalemia on the action potential of cardiac muscle has been described.
Progressive increase in extracellular potassium concentration produces progressive decrease in the resting membrane potential.
This, in turn, decreases the upstroke velocity and results in a slow imitravemitricular conduction amid increased duration of the QRS complex on conventional electro-
